^
    Back
    Association details:
    Biomarker:IDH2 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Idhifa (enasidenib) (IDH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2021
    Title:

    EFFICACY AND SAFETY OF ENASIDENIB AND AZACITIDINE COMBINATION IN PATIENTS WITH IDH2 MUTATED ACUTE MYELOID LEUKEMIA AND NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

    Published date:
    05/12/2021
    Excerpt:
    In the mIDH2 R/R AML cohort, 7 pts received the ENA+AZA+VEN triplet...The CR/CRi rate was 86%...ENA+AZA+VEN may be an effective combination therapy for mIDH2 R/R AML, even in patients having received prior enasidenib.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Exp Hematol Oncol
    Title:

    Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

    Published date:
    01/04/2021
    Excerpt:
    We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.
    DOI:
    10.1186/s40164-020-00186-y